Nebulized arformoterol in patients with COPD: A 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial
References (32)
- et al.
Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study
Lancet
(1997) The effect of inhaled beta2-agonists on clinical outcomes in chronic obstructive pulmonary disease
J Allergy Clin Immunol
(2002)- et al.
Biological actions of for moterol isomers
Pulm Pharmacol Ther
(2002) - et al.
Dyspnea is abetter predictor of 5-year survival than airway obstruction in patients with COPD
Chest
(2002) - et al.
Comparison of the anti-bronchoconstrictor activities of inhaled formoterol, its (R, R)- and (S, S)-enantiomers and salmeterrol in therhesus monkey
Pulm Pharmacol Ther
(2001) - et al.
Device selection and outcomes of aero-sol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology
Chest
(2005) Chronic obstructive pulmonary disease: Definition and epidemio!ogy
Respir Care
(2003)Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease
Am J Respir Crit Care Med
(1995)- et al.
Global strategy for the diagnosis, management, and prevention of chron-ic obstructive pulmonary disease
Am J Respir Crit Care Med
(2001) - et al.
Long-active beta2-agoniss for poorly reversible chronic obstructive pulmonary disease
Cochrane Database Sys Rev
(2006)
Guidelines for the use of nebulizers in the home and at domiciliary sites
Chest
(1996)
European Respiratory Society Guidelines on the use of nebulizers
Eur Respir J
(2001)
BTS guidelines for the management of chronic obstructive pulmonary disease
Thorax
(1997)
Steric aspects of ago- nism and antagonism at beta- adrenoceptors: Synthesis of and pharmacological experiments with the enantiomers of formoterol and diastereomers
Chirality
(1991)
Effects of enantiomers of beta2-agonists on ACh release and smooth muscle contraction in the trachea
Am J Physiol
(1998)
The effect of the enantiomers of formoterol on inherent and in duced tone in guinea-pig trachea and human bronchus
Naunyn Schmiedebergs Arch Pharmacol
(2000)
Cited by (58)
Long-acting bronchodilators improve Health Related Quality of Life in patients with COPD
2013, Respiratory MedicineCitation Excerpt :HRQoL/HS were evaluated in all studies using the SGRQ. The study duration ranged from 12 weeks to 12 months, and comparators of formoterol were terbutalin [22], salmeterol [23], ipratropium [24,25], theophylline [26], different formulations of formoterol [27] and placebo [23–29]. Formoterol was tested as dry powder inhaler (DPI) Aerolizer at dose of 12/24 μg bis in die (BID) [2426,27,28], Novolizer 12/24 μg BID [29], Turbohaler 18 μg BID [25], 9 μg BID or BID + 4.5 μg prn [22], and nebulized arformoterol via PARI LC PLUS nebulizer at doses of 15/20/25 μg BID [23,27,28] and 50 μg [23].
A Retrospective Review of an Inhaler to Nebulizer Therapeutic Interchange Program Across a Health System
2023, Journal of Pharmacy PracticeNebulized therapies in copd: Past, present, and the future
2020, International Journal of COPD
Copyright © 2007 Published by Elsevier Inc.